AMINOLEVULINIC ACID

/static/temp/default.svg

Search structure


Synonyms	.delta.-aminolevulinic acid Aminolevulinic acid Levulan
Status
Molecule Category	UNKNOWN
ATC	L01XD04
UNII	88755TAZ87
EPA CompTox	DTXSID8048490


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	ZGXJTSGNIOSYLO-UHFFFAOYSA-N
Smiles	NCC(=O)CCC(=O)O
InChI	InChI=1S/C5H9NO3/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C5H9NO3
Molecular Weight	131.13
AlogP	-0.62
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	4.0
Polar Surface Area	80.39
Molecular species	ACID
Aromatic Rings	0.0
Heavy Atoms	9.0

Assay Description	Organism	Bioactivity	Reference
Inhibition of 26S proteasome activity in human U251 cells at 100 uM after 48 hrs relative to control	Homo sapiens	100.0 %
Inhibition of 26S proteasome activity in human U251 cells at 100 uM after 48 hrs in presence of N-acetyl-L-cysteine relative to control	Homo sapiens	102.0 %
Cytotoxicity against human A431 cells assessed as reduction in cell viability at 2 uM preincubated for 4 hrs followed by 5 J/cm'-2 red light irradiation measured after 24 hrs by MTT assay relative to control	Homo sapiens	43.0 %
Cytotoxicity against human A431 cells assessed as reduction in cell viability at 2 uM preincubated for 4 hrs followed by 90 J/cm'-2 ultrasound irradiation measured after 24 hrs by MTT assay relative to control	Homo sapiens	31.0 %
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600)	Staphylococcus aureus subsp. aureus	8.53 %
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600)	Escherichia coli	5.31 %
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)	Klebsiella pneumoniae	13.51 %
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)	Pseudomonas aeruginosa	12.16 %
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600	Acinetobacter baumannii	27.7 %
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630	Candida albicans	0.21 %
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)	Cryptococcus neoformans	-6.69 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	31.45 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.08 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.08 %

Cross References

Resources	Reference
ChEBI	356416
ChEMBL	CHEMBL601
DrugBank	DB00855
DrugCentral	166
FDA SRS	88755TAZ87
Human Metabolome Database	HMDB0001149
Guide to Pharmacology	4784
KEGG	C00430
PDB	FVT
PharmGKB	PA10015
PubChem	137
SureChEMBL	SCHEMBL8243
ZINC	ZINC000003782550

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).